IL4 and atopic eczema: In keratinocytes, BCP specifically counteracts Th2-driven inflammation by suppressing the IL-4/IL-13–MAPK–early growth response 1 (EGR1) axis, which otherwise promotes thymic stromal lymphopoietin (TSLP), a central epithelial alarmin in atopic dermatitis [30,110].